Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of AMG 334 for Migraine Prevention
2014-004464-38Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing AMG 334 with Placebo (2 arms). Primary endpoint: Change from baseline in mean monthly migraine days. Started May 2015; status: completed.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on 2014-004464-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004464-38.